Type Condition

Huntsville, AL

197 Clinical Trials near Huntsville, AL

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Zilebesiran for High Blood Pressure

Huntsville, Alabama
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

375 Participants Needed

CIN-103 for Irritable Bowel Syndrome

Huntsville, Alabama
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the following visits: * Screening Period (1 Visit) * Baseline Period (1 Visit) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued participation. * 12-Week Treatment Period (5 Visits) * Study drug taken twice daily by mouth. * Will complete daily diaries and other PROs as described in the protocol. * Follow- Up Period (1 Visit) Researchers will compare CIN-103 Dose 1, CIN-103 Dose 2, and placebo, to evaluate the clinical response to multiple dose strengths of CIN-103 relative to placebo on abdominal pain and stool consistency along with safety and tolerability.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

450 Participants Needed

RSV mRNA Vaccine for Respiratory Syncytial Virus Immunization

Huntsville, Alabama
This trial tests a new RSV vaccine that uses tiny fat particles to help deliver it into the body. It aims to see if the vaccine is safe and effective in healthy adults aged 18-50 and those aged 60 and older. The vaccine works by teaching the immune system to recognize and fight RSV.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

865 Participants Needed

Rencofilstat for NASH with Advanced Liver Fibrosis

Huntsville, Alabama
This trial tests Rencofilstat, a medication that may improve liver damage, in adults with NASH and significant liver fibrosis. The drug works by reducing liver scarring and damage.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

120 Participants Needed

Oral Azacitidine for Acute Myeloid Leukemia

Huntsville, Alabama
The purpose of this study is to assess the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in a cohort of Japanese participants ≥ 55 years of age with Acute Myeloid Leukemia (AML) and in complete remission/complete remission with incomplete blood count recovery after conventional induction chemotherapy with or without consolidation chemotherapy.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55+

19 Participants Needed

Abelacimab vs. Rivaroxaban for Atrial Fibrillation

Huntsville, Alabama
This trial is testing a new blood thinner called abelacimab to see if it causes less bleeding compared to an existing drug, rivaroxaban. It focuses on patients with atrial fibrillation who are at a higher risk of stroke. Blood thinners help prevent strokes by stopping clots, but they can also cause bleeding.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55+

1287 Participants Needed

HM15211 for Non-alcoholic Steatohepatitis (NASH)

Huntsville, Alabama
This trial is testing a medication called HM15211 to see if it can help people with a liver disease called NASH. The study will check if the medication is safe and effective over a period of time.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

215 Participants Needed

Zanubrutinib for Lymphoma

Huntsville, Alabama
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

90 Participants Needed

Nivolumab Safety for Cancer

Huntsville, Alabama
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

1500 Participants Needed

cAD3-Sudan Vaccine for Sudan Ebolavirus

Huntsville, Alabama
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

200 Participants Needed

Zelquistinel for Depression

Huntsville, Alabama
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64

164 Participants Needed

Ashwagandha for Menopause

Huntsville, Alabama
The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on symptoms of menopause and hormone levels, as compared to a placebo.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:40 - 55
Sex:Female

90 Participants Needed

Lifestyle Intervention for Alzheimer's Disease

Huntsville, Alabama
Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimodal lifestyle interventions can significantly delay the onset of Alzheimer's dementia in individuals with high risk for Alzheimer's or with Mild Cognitive Impairment (MCI). These interventions may be less effective when initiated after dementia has already been diagnosed or is more advanced. This study has two primary goals. The first goal is to assess attitudes around dementia risk for participants throughout the study as they learn of their personalized risk and possible lifestyle factors that may modify that risk. The second goal is to serve as a logistical pilot for the implementation of data collection and processing and multimodal lifestyle intervention to reduce the risk factors of dementia in individuals without current cognitive impairment but who are at high risk of progression to dementia. Secondary goals of this study include better defining what factors contribute the most risk to dementia and identifying sub-types of dementia defined by different genetic and molecular risk factors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65 - 75

200 Participants Needed

Niagen®+ for Healthy Aging

Huntsville, Alabama
This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:40 - 65

70 Participants Needed

Ashwagandha Extract for Stress

Huntsville, Alabama
The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on stress levels, with secondary outcomes of cognition, energy, and sleep, as compared to a placebo.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:30 - 59
Sex:Female

60 Participants Needed

Shockwave Therapy for Coronary Artery Disease

Huntsville, Alabama
This investigational device exemption (IDE) study is to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System with the Shockwave C2+ 2Hz Coronary IVL Catheter to treat de novo, calcified, stenotic, coronary lesions prior to stenting.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

145 Participants Needed

Ear Tube Insertion Device for Ear Infections

Huntsville, Alabama
This trial is testing a device that helps doctors put small tubes in children's eardrums. It targets kids who need this procedure to prevent ear infections. The device works by making it easier to place the tubes, which help drain fluid from the ear.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 13

66 Participants Needed

Left Atrial Appendage Exclusion for Stroke Prevention

Huntsville, Alabama
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

6573 Participants Needed

Cognitive Behavioral Therapy for Alcohol Use Disorder in HIV

Huntsville, Alabama
This study is designed to examine the efficacy of a brief intervention plus a cognitive-behavioral intervention compared to brief intervention alone to address unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among people living with HIV in Alabama.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

308 Participants Needed

Defibrillator Lead for Rapid Heartbeat

Huntsville, Alabama
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:12+

998 Participants Needed

Why Other Patients Applied

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

Left Atrial Appendage Occlusion vs. NOAC for Atrial Fibrillation

Huntsville, Alabama
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2650 Participants Needed

VNS for Bipolar Depression

Huntsville, Alabama
This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

6800 Participants Needed

Biofeedback + Injection for Bowel Incontinence

Birmingham, Alabama
This trial is for patients with severe fecal incontinence who haven't responded to initial treatments. It compares two methods: muscle training and a treatment that adds bulk to the rectum. The goal is to see which method better reduces incontinence episodes.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

275 Participants Needed

WiSE CRT System for Heart Failure

Huntsville, Alabama
This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

300 Participants Needed

Carotid Stenting vs. Endarterectomy for Carotid Stenosis

Huntsville, Alabama
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical management will be uniform for all randomized treatment groups and will be centrally directed.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:35 - 100

2486 Participants Needed

Symphony Thrombectomy for Pulmonary Embolism

Huntsville, Alabama
Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

109 Participants Needed

Intervention Programs for Childhood Behavior

Huntsville, Alabama
The primary purpose of this project is to test a comprehensive, two-part intervention with ReACT and a recently adapted, Coping Power+ Program. ReACT and PBIS are school-wide universal interventions. Coping Power and Coping Power+ are targeted preventive interventions designed to assist at-risk 7th grade students to improve their coping with interpersonal stressors during middle school. This project will evaluate the effects of the program on teacher, student and parent perceptions of school climate, student behavior, social-emotional competence, disciplinary infractions, and identity for 7th grade students in Coping Power or Coping Power+
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:10 - 14

1093 Participants Needed

TAVR for Aortic Stenosis

Huntsville, Alabama
This trial tests advanced heart valves that can be inserted without open-heart surgery in patients with a narrowed and stiff aortic valve due to calcium buildup. The new valve is placed through a small cut and guided to the heart, where it replaces the damaged valve. This minimally invasive procedure has recently become the only lifesaving solution for patients who cannot tolerate standard surgical valve replacement.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

2250 Participants Needed

PCI vs Medical Management for Aortic Stenosis

Huntsville, Alabama
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

4000 Participants Needed

ChEVAS for Abdominal Aortic Aneurysm

Huntsville, Alabama
Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex Abdominal Aortic Aneurysms.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

13 Participants Needed

1...345...7

Know someone looking for new options? Spread the word

Match to a Trial